BR112022002433A2 - Composição farmacêutica oral - Google Patents

Composição farmacêutica oral

Info

Publication number
BR112022002433A2
BR112022002433A2 BR112022002433A BR112022002433A BR112022002433A2 BR 112022002433 A2 BR112022002433 A2 BR 112022002433A2 BR 112022002433 A BR112022002433 A BR 112022002433A BR 112022002433 A BR112022002433 A BR 112022002433A BR 112022002433 A2 BR112022002433 A2 BR 112022002433A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
oral pharmaceutical
active ingredient
medium
long period
Prior art date
Application number
BR112022002433A
Other languages
English (en)
Portuguese (pt)
Inventor
YOSHIMURA Motoyasu
Fujii Takuya
Kamada Naoki
TOGASHI Ryohei
AONO Ryuta
Wang Xinyu
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112022002433A2 publication Critical patent/BR112022002433A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112022002433A 2019-08-13 2020-08-13 Composição farmacêutica oral BR112022002433A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2019/031895 WO2021029020A1 (ja) 2019-08-13 2019-08-13 経口医薬組成物
PCT/JP2020/030776 WO2021029429A1 (ja) 2019-08-13 2020-08-13 経口医薬組成物

Publications (1)

Publication Number Publication Date
BR112022002433A2 true BR112022002433A2 (pt) 2022-12-13

Family

ID=74569440

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022002433A BR112022002433A2 (pt) 2019-08-13 2020-08-13 Composição farmacêutica oral
BR112022002436A BR112022002436A2 (pt) 2019-08-13 2020-08-13 Composição farmacêutica oral contendo composto heterocíclico

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022002436A BR112022002436A2 (pt) 2019-08-13 2020-08-13 Composição farmacêutica oral contendo composto heterocíclico

Country Status (15)

Country Link
US (4) US20220273647A1 (https=)
EP (2) EP4015001A4 (https=)
JP (7) JPWO2021029020A1 (https=)
KR (2) KR20220046625A (https=)
CN (2) CN114222562A (https=)
AU (2) AU2020328351B2 (https=)
BR (2) BR112022002433A2 (https=)
CA (2) CA3150751A1 (https=)
IL (2) IL290469B2 (https=)
MX (3) MX2022001758A (https=)
MY (2) MY208261A (https=)
PH (2) PH12022550347A1 (https=)
TW (2) TWI870441B (https=)
WO (3) WO2021029020A1 (https=)
ZA (2) ZA202202319B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
CN118742293A (zh) * 2022-01-31 2024-10-01 住友精化株式会社 药物控释制剂用组合物和药物控释制剂
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤
AU2024247059A1 (en) * 2023-03-29 2025-10-30 Merck Sharp & Dohme (Uk) Limited Controlled release pde10a formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (https=) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EP2911670A1 (en) * 2012-10-25 2015-09-02 Otsuka Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
CN106667969A (zh) * 2017-02-23 2017-05-17 佛山市弘泰药物研发有限公司 一种依匹哌唑缓释胶囊及其制备方法
JP6886654B2 (ja) 2017-04-11 2021-06-16 学校法人帝京大学 抗カンジダ活性組成物
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物

Also Published As

Publication number Publication date
CN114222575A (zh) 2022-03-22
MX2022001758A (es) 2022-05-13
JPWO2021029020A1 (https=) 2021-02-18
PH12022550349B1 (en) 2024-03-06
MY208261A (en) 2025-04-29
MY208267A (en) 2025-04-29
JPWO2021029429A1 (https=) 2021-02-18
AU2020327792A1 (en) 2022-03-24
TW202120090A (zh) 2021-06-01
CA3150751A1 (en) 2021-02-18
PH12022550347A1 (en) 2022-12-12
KR20220046625A (ko) 2022-04-14
AU2020328351A1 (en) 2022-03-24
JP2022180531A (ja) 2022-12-06
WO2021029430A1 (ja) 2021-02-18
JPWO2021029430A1 (https=) 2021-02-18
EP4015002A4 (en) 2023-06-07
AU2020327792B2 (en) 2026-03-05
TWI870441B (zh) 2025-01-21
CA3150827A1 (en) 2021-02-18
IL290472A (en) 2022-04-01
IL290469B2 (en) 2025-08-01
TW202120091A (zh) 2021-06-01
IL290469B1 (en) 2025-04-01
CN114222562A (zh) 2022-03-22
WO2021029429A1 (ja) 2021-02-18
BR112022002436A2 (pt) 2022-12-13
TW202517267A (zh) 2025-05-01
MX2025006039A (es) 2025-07-01
EP4015001A4 (en) 2023-06-14
JP7148733B2 (ja) 2022-10-05
JP2025072595A (ja) 2025-05-09
TWI870442B (zh) 2025-01-21
MX2022001759A (es) 2022-05-13
JP2022132411A (ja) 2022-09-08
EP4015002A1 (en) 2022-06-22
JP2025074104A (ja) 2025-05-13
IL290469A (en) 2022-04-01
WO2021029020A1 (ja) 2021-02-18
ZA202202319B (en) 2024-06-26
TW202517266A (zh) 2025-05-01
US20250057835A1 (en) 2025-02-20
KR20220046624A (ko) 2022-04-14
EP4015001A1 (en) 2022-06-22
US20220273647A1 (en) 2022-09-01
US20250127776A1 (en) 2025-04-24
US20220280418A1 (en) 2022-09-08
JP7110495B2 (ja) 2022-08-01
ZA202202320B (en) 2024-06-26
AU2020328351B2 (en) 2026-03-05
PH12022550349A1 (en) 2022-12-12
JP7635187B2 (ja) 2025-02-25

Similar Documents

Publication Publication Date Title
BR112022002433A2 (pt) Composição farmacêutica oral
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
MX2023014946A (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal.
MX2021002382A (es) Sales y formas cristalinas de modulador alosterico positivo gabaa.
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
EP4560024A3 (en) Deuterated analogs of d-serine and uses thereof
EA202190245A1 (ru) Производные спирохромана
MX395554B (es) Composición farmacéutica de clozapina de liberación prolongada.
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
WO2020009675A3 (en) Solid oral pharmaceutical compositions of linagliptin
MX2023010506A (es) Composiciones que comprenden profarmacos de escision enzimatica y nafamostat de liberacion controlada y metodos de uso de estos.
WO2019209217A3 (en) Modified release formulations of flurbiprofen
BR112016014523A2 (pt) Composições de higiene oral e uso
UY38072A (es) Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
BR112021023664A2 (pt) Dispositivo gerador de aerossol compreendendo um bocal de uso único
CO2020006701A2 (es) Composiciones farmacéuticas orales de lorazepam resistentes al alcohol
UA113233U (uk) Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента
MX2018007272A (es) Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales.
TR201722852A2 (tr) Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]